Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

DSpace/Manakin Repository

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Citable link to this page

 

 
Title: Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
Author: Witt, A E; Lee, C-W; Lee, T I; Azzam, D J; Wang, B; Caslini, C; Petrocca, F; Grosso, J; Jones, M; Cohick, E B; Gropper, A B; Wahlestedt, C; Richardson, A L; Shiekhattar, R; Young, R A; Ince, T A

Note: Order does not necessarily reflect citation order of authors.

Citation: Witt, A. E., C. Lee, T. I. Lee, D. J. Azzam, B. Wang, C. Caslini, F. Petrocca, et al. 2017. “Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.” Oncogene 36 (12): 1707-1720. doi:10.1038/onc.2016.337. http://dx.doi.org/10.1038/onc.2016.337.
Full Text & Related Files:
Abstract: Tumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are resistant to conventional cancer therapies and play essential roles in metastasis and tumour relapse. Despite this realization and great interest in CSCs, it has been difficult to develop CSC-targeted treatments due to our limited understanding of CSC biology. Here, we present evidence that specific histone deacetylases (HDACs) play essential roles in the CSC phenotype. Utilizing a novel CSC model, we discovered that the HDACs, HDAC1 and HDAC7, are specifically over-expressed in CSCs when compared to non-stem-tumour-cells (nsTCs). Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is sufficient to augment the CSC phenotype. We also demonstrate that clinically available HDAC inhibitors (HDACi) targeting HDAC1 and HDAC7 can be used to preferentially target CSCs. These results provide actionable insights that can be rapidly translated into CSC-specific therapies.
Published Version: doi:10.1038/onc.2016.337
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364039/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630581
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters